Piramal Pharma Solutions (PPS) has announced the implementation of “various tools to unlock API manufacturing capacity and support client needs in drug development and on-patent projects” at its 40-hectare site at Digwal in the Indian state of Telangana. This came shortly after its new API plant at Aurora, Ontario, came online.
Indian-based CDMO Piramal Pharma Solutions (PPS) is to invest about £55 million to expand two sites in the UK. It will expand its antibody-drug conjugate (ADC) capabilities at Grangemouth in Scotland and new API infrastructure at Morpeth in north-east England.
India-based CDMO Piramal Pharma has taken a 27.78% equity stake in Yapan Bio of Hyderabad, which provides process development, scale-up and cGMP manufacturing of vaccines and biologics/bio-therapeutics of all kinds, including recombinant and RNA/DNA vaccines, gene therapies and monoclonal antibodies.
Pharmaceutical CDMO Piramal Pharma Solutions (PPS) is to invest about $32 million to expand its former Ash Stevens API manufacturing site at Riverview, Michigan. This will add 2,300 m2 of space, including 780 m2 of production space.
Via CA Clover Intermediate II Investments, private equity firm the Carlyle Group is to invest about $940 million in fresh equity capital for a 20% stake in Piramal Pharma, the healthcare subsidiary of Indian conglomerate Piramal Enterprises (PEL). This values the business at $2,775 million with an upside component of up to $360 million depending on the company’s performance this financial year.